rs140845195
Variant summary
Our verdict is Pathogenic. Variant got 22 ACMG points: 22P and 0B. PVS1PM2PP3_StrongPP5_Very_Strong
The NM_001182.5(ALDH7A1):c.1566-1G>T variant causes a splice acceptor change. The variant allele was found at a frequency of 0.00000873 in 1,604,084 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/2 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000083 ( 0 hom. )
Consequence
ALDH7A1
NM_001182.5 splice_acceptor
NM_001182.5 splice_acceptor
Scores
5
1
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 5.88
Genes affected
ALDH7A1 (HGNC:877): (aldehyde dehydrogenase 7 family member A1) The protein encoded by this gene is a member of subfamily 7 in the aldehyde dehydrogenase gene family. These enzymes are thought to play a major role in the detoxification of aldehydes generated by alcohol metabolism and lipid peroxidation. This particular member has homology to a previously described protein from the green garden pea, the 26g pea turgor protein. It is also involved in lysine catabolism that is known to occur in the mitochondrial matrix. Recent reports show that this protein is found both in the cytosol and the mitochondria, and the two forms likely arise from the use of alternative translation initiation sites. An additional variant encoding a different isoform has also been found for this gene. Mutations in this gene are associated with pyridoxine-dependent epilepsy. Several related pseudogenes have also been identified. [provided by RefSeq, Jan 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 22 ACMG points.
PVS1
?
Splicing variant, LoF is a know mechanism of disease,
PM2
?
Very rare variant in population databases, with high coverage;
PP3
?
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
?
Variant 5-126545020-C-A is Pathogenic according to our data. Variant chr5-126545020-C-A is described in ClinVar as [Pathogenic]. Clinvar id is 374140.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-126545020-C-A is described in Lovd as [Pathogenic]. Variant chr5-126545020-C-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ALDH7A1 | NM_001182.5 | c.1566-1G>T | splice_acceptor_variant | ENST00000409134.8 | |||
ALDH7A1 | NM_001201377.2 | c.1482-1G>T | splice_acceptor_variant | ||||
ALDH7A1 | NM_001202404.2 | c.1374-1G>T | splice_acceptor_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ALDH7A1 | ENST00000409134.8 | c.1566-1G>T | splice_acceptor_variant | 1 | NM_001182.5 | P4 |
Frequencies
GnomAD3 genomes ? AF: 0.0000131 AC: 2AN: 152110Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
2
AN:
152110
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 250932Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135692
GnomAD3 exomes
AF:
AC:
4
AN:
250932
Hom.:
AF XY:
AC XY:
3
AN XY:
135692
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000826 AC: 12AN: 1451974Hom.: 0 Cov.: 29 AF XY: 0.00000968 AC XY: 7AN XY: 722978
GnomAD4 exome
AF:
AC:
12
AN:
1451974
Hom.:
Cov.:
29
AF XY:
AC XY:
7
AN XY:
722978
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000131 AC: 2AN: 152110Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74300
GnomAD4 genome
?
AF:
AC:
2
AN:
152110
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74300
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
?
AF:
AC:
1
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Pyridoxine-dependent epilepsy Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Aug 29, 2023 | This sequence change affects an acceptor splice site in intron 17 of the ALDH7A1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in the loss of 5 amino acid residue(s), but is expected to preserve the integrity of the reading-frame. For these reasons, this variant has been classified as Pathogenic. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that disruption of this splice site results in the activation of a cryptic splice site in exon 18 (PMID: 23350806). ClinVar contains an entry for this variant (Variation ID: 374140). This variant is also known as c.1482-1G>T. Disruption of this splice site has been observed in individual(s) with pyridoxine dependent epilepsy (PMID: 17068770, 23350806). It has also been observed to segregate with disease in related individuals. This variant is present in population databases (rs140845195, gnomAD 0.004%). - |
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Nov 05, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 31, 2023 | Observed in the homozygous state, with a pathogenic variant on the opposite allele (in trans), or with a second ALDH7A1 variant, phase unknown, in individuals with pyridoxine-dependent epilepsy in the published literature and not observed in homozygous state in controls (PMID: 30043187, 17068770); Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Previously reported as c.1482-1 G>T due to alternative nomenclature; This variant is associated with the following publications: (PMID: 31589614, 29286531, 31990480, 17068770, 36011376, 30043187, 31440721, 31623504) - |
Seizure;C3278923:Ventriculomegaly Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 15, 2015 | - - |
ALDH7A1-related condition Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 02, 2024 | The ALDH7A1 c.1566-1G>T variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in individuals with pyridoxine-dependent epilepsy (Plecko et al. 2007. PubMed ID: 17068770; Pérez et al. 2013. PubMed ID: 23350806; Coughlin et al. 2019. PubMed ID: 30043187. Table S2). This variant is reported in 0.0035% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Variants that disrupt the consensus splice acceptor site in ALDH7A1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Pyridoxine-dependent epilepsy caused by ALDH7A1 mutant Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Sep 04, 2023 | This sequence change in ALDH7A1 occurs within the canonical splice acceptor site of intron 17. It is predicted to cause the activation of the cryptic splice site in exon 18 leading to an in-frame five amino acid deletion (removes amino acids 495-499) which has been confirmed by RT-PCR on patient lymphoblast cells (PMID: 23350806). The highest population minor allele frequency in the population database gnomAD v2.1 is 0.004% (4/113,332 alleles) in the European (non-Finnish) population. This variant has been detected in multiple individuals with pyridoxine-dependent epilepsy, homozygous and compound heterozygous with a second pathogenic variant (PMID: 23350806, 17068770, 31990480, 30043187). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.6.1, this variant is classified as PATHOGENIC. Following criteria are met: PVS1_Moderate, PM3_VeryStrong, PM2_Supporting - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
Cadd
Pathogenic
Dann
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
D;D;D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AL_spliceai
Position offset: -1
Find out detailed SpliceAI scores and Pangolin per-transcript scores at